Plain-English translation of NCT06483555 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding , a medication that blocks cancer cell growth signals, to standard chemotherapy ( and nab-paclitaxel) can help people with advanced pancreatic cancer. First, your tumor will be tested using a tool called PurIST to determine its type. If you have a 'basal-like' pancreatic cancer, you may receive the medication combined with chemotherapy; if your tumor is 'classical,' you'll receive standard treatment.
Pancreatic cancer is very difficult to treat, and doctors need better options for patients whose tumors have specific characteristics. This trial exists to see if targeting a specific growth pathway with this medication, when added to chemotherapy, can help more patients live longer with this aggressive disease.
You likely qualify if…
You likely don't qualify if…
You will first have a tumor biopsy or tissue test to determine your cancer type using the PurIST classifier. Depending on your tumor type, you may receive chemotherapy with or without the targeted medication through regular infusions at the cancer center. You'll have blood tests, imaging scans, and follow-up visits to track how well the treatment is working and manage any side effects. Researchers will monitor your health and survival throughout the study, which is expected to take place over several months to years.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States